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Aim To analyze the effects of highly selective blocker GAT1, 
NO-711, and substrate inhibitor GAT3, β-alanine, on the ini-
tial velocity of [3H]GABA uptake by cortical, hippocampal, 
and thalamic nerve terminals (synaptosomes) after perina-
tal hypoxia.
Methods Animals were divided into two groups: control 
(n = 17) and hypoxia (n = 12). Rats in the hypoxia group 
underwent hypoxia and seizures (airtight chamber, 4% O2 
and 96% N2) at the age of 10-12 postnatal days and were 
used in the experiments 8-9 weeks after hypoxia.
Results In cortical synaptosomes, the effects of NO-711 
(30 μΜ) and β-alanine (100 μΜ) on [3H]GABA uptake were 
similar in control and hypoxia groups. In hippocampal syn-
aptosomes, NO-711 inhibited 84.3% of the initial velocity 
of [3H]GABA uptake in normal conditions and 80.1% after 
hypoxia, whereas the effect of β-alanine was increased 
after hypoxia from 14.4% to 22.1%. In thalamic synapto-
somes, the effect of NO-711 was decreased by 79.6% in 
controls and by 70.9% in hypoxia group, whereas the ef-
fect of β-alanine was increased after hypoxia from 20.2% 
to 30.2%.
Conclusions The effectiveness of β-alanine to influence 
GABA uptake was increased in hippocampal and thalamic 
nerve terminals as a result of perinatal hypoxia and the ef-
fectiveness of NO-711 in thalamic nerve terminals was de-
creased. These results may indicate changes in the ratio of 
active GAT1/GAT3 expressed in the plasma membrane of 
nerve terminals after perinatal hypoxia. We showed a pos-
sibility to modulate non-GAT1 GABA transporter activity 
in different brain regions by exogenous and endogenous 
β-alanine.
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Perinatal hypoxia leads to multiple chronic neurological 
deficits including mental retardation, learning and mem-
ory disability, behavioral abnormalities, and even epilepsy 
(1). Pathological consequences of early life hypoxia may be 
a result of disturbance of the highly regulated maturation 
process. γ-Aminobutyric acid (GABA) as the first functional 
neurotransmitter in the developing brain fulfils an impor-
tant signaling function in synapse formation and network 
construction (2). Hypoxic injury of the developing brain is 
mainly studied using the hypoxia model, in which rat pups 
undergo a brief exposure to graded global hypoxia in an 
airtight chamber (3). This showed a particular vulnerabili-
ty of GABAergic neurons (4-6) and a long-lasting decrease 
in thresholds to convulsant action in adult rats that under-
went hypoxia at an early age (3,6,7). In rats 10-12 postnatal 
days old, a single brief episode of moderately graded global 
hypoxia led to the development of tonic-clonic activity and 
caused a long-lasting (70-80 days after hypoxia) selective 
increase in seizure susceptibility in hippocampal slices (3).
Sodium- and chloride-dependent GABA transporters 
(GATs), which belong to the SLC6 superfamily of Na+ -de-
pendent transporters, terminate inhibitory synaptic trans-
mission, ie, after release from presynaptic nerve terminals 
GABA is rapidly removed from the extracellular space by 
GATs, thereby maintaining optimal ambient level of the 
neurotransmitter. Chronic neurological abnormalities, 
which develop after hypoxia at an early age, may be asso-
ciated with changes in the functioning of GATs (8-10). Our 
previous experiments on rats that underwent perinatal hy-
poxia demonstrated a long-lasting increase in the ambient 
GABA level in cortical and hippocampal nerve terminals, 
whereas the thalamus was less sensitive to perinatal hy-
poxia, and thalamic GATs, in contrast to cortical and hip-
pocampal ones, had a lower affinity to GABA (11).
Four types of GABA transporters are expressed in the plas-
ma membrane of presynaptic nerve terminals and glial 
cells, that is, GAT1, GAT2, GAT3, and GAT4. GATs serve as one 
of the main targets for drugs in the treatment of neurologi-
cal disorders, and so GABA uptake inhibitors are very prom-
ising agents with potential application in epilepsy, anxiety, 
pain, drug abuse, sleep disorders, and others disorders 
(8,9). The two most likely candidates for the maintenance 
of optimal ambient level of GABA in the brain are GAT1 and 
GAT3 (8). 1,2,5,6-Tetrahydro-1-(2-(((diphenylmethylene)
amino)oxy)ethyl)-3-pyridinecarboxylic acid hydrochloride 
(NO-711) is a potent and selective GAT1 inhibitor with an 
IC50 of 0.38 µM; IC50 for GAT2 and GAT3 are 729 and 349 
µM, respectively (12,13). Noteworthy, mixed GAT inhibitors 
are shown to have much broader spectrum of anticonvul-
sant activity than compounds with affinity only for GAT1. 
There are reports suggesting that non-GAT1 inhibitors are 
very interesting as potential candidates for future epilepsy 
treatment (8,14). Since the physiological role of GATs other 
than GAT1 is not fully determined, these inhibitors can also 
be pharmacological tools for the research on the biological 
role of non-GAT1 GABA transporters (15). In this context, 
there is a great need for the analysis of GABA uptake inhibi-
tors, which can be used as research tools or potential drugs 
(16). β-alanine, a structural intermediate between α-amino 
acid (glycine, glutamate) and γ-amino acid (GABA) neu-
rotransmitters, is a substrate inhibitor of GAT3. It should be 
underlined that exogenous β-alanine is carried across the 
blood brain barrier (BBB) into the central nervous system 
(CNS) via a taurine-sensitive β-amino acid transporter (17).
The aim of the research was to analyze the effects of high-
ly-selective blocker of GAT1, NO-711, and substrate inhibi-
tor of GAT3, β-alanine, on the initial velocity of [3H]GABA 
uptake by cortical, hippocampal, and thalamic nerve ter-
minals isolated from control rats (8-9 weeks old) and rats 
(8-9 weeks old) that preliminary underwent hypoxia and 
seizures at the age of 10-12 postnatal days (perinatal hy-
poxia). The research question was how to modulate long-
lasting changes in GABA uptake (and ambient level of 
GABA) in different brain regions after perinatal hypoxia/sei-
zures taking into account that these changes might result 
from altered functioning of different types of GATs.
MaTeriaLs aND MeTHODs
Materials
β-Alanine, aminooxyacetic acid, N-2-hydroxyethylpiper-
azine-n-2-ethanesulfonic acid (HEPES), EDTA, D-glucose, 
sucrose, NO-711, Whatman GF/C filters, analytical grade 
salts were purchased from Sigma (St. Louis, MO, USA). 
[3H]GABA (94 Ci/mmol) and Organic Counting Scintil-
lant (OCS) were received from Amersham (Little Chal-
font, UK).
ethical considerations
Experiments were carried out in accordance with the Eu-
ropean Guidelines and International Laws and Policies. We 
used Wistar rats (n = 29) from the vivarium of MD Strazhesko 
Institute of Cardiology, Medical Academy of Sciences of 
Ukraine. Animals were kept in the animal facilities of the 
Palladin Institute of Biochemistry of National Acade-
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my of Sciences of Ukraine, Kyiv, in accordance with the Eu-
ropean Guidelines and International Laws and Policies (18). 
They were housed in a quiet, temperature-controlled room 
(22-23°C) and were provided with water and dry food pel-
lets ad libitum. Rats were decapitated and the brain was re-
moved. All procedures conformed to the guidelines of the 
Palladin Institute of Biochemistry. Before starting the experi-
ments in 2012, the protocols were approved by the Animal 
Care and Use Committee of the Palladin Institute of Bio-
chemistry (Protocol from 19/09-2012). All efforts were made 
to minimize animal suffering and use only the number of 
animals necessary to produce statistically significant data.
exposure to hypoxia
Wistar rats, males, were divided into two groups: vivarium 
control (n = 12) and hypoxia (n = 12), also 5 control animals 
were used for the analysis of time-dependence of inhibito-
ry effects. At postnatal days 10-12, animals were removed 
from the litter and placed in an airtight chamber infused 
by atmosphere composed of 4% O2 and 96% N2. The ex-
posure in the chamber lasted for 12 minutes until strongly 
pronounced tonico-clonic seizures developed (3). Animals 
exposed to hypoxia and their littermates were taken in ex-
periments 8-9 weeks after the hypoxia episode.
isolation of synaptosomes
Control and experimental animals from each litter were 
analyzed simultaneously. After decapitation, the brain was 
quickly removed and immediately placed in ice-cold solu-
tion (0.32 M sucrose, 5 mM HEPES-NaOH, pH 7.4, 0.2 mM 
EDTA). Then the motor zone of the cortex, hippocampus, 
and thalamus were rapidly removed and homogenized in 
ice-cold solution (0.32 M sucrose, 5 mM HEPES-NaOH, pH 
7.4, 0.2 mM EDTA) taken in the ratio of 1:10 (weight/volume). 
The homogenates were centrifuged (2500 g, 5 minutes) and 
the supernatants were carefully removed and again centri-
fuged at 15 000 g for 12 minutes for isolation of crude synap-
tosomal fraction. Purified synaptosomes were prepared by 
Ficoll-400 density gradient centrifugation of crude prepa-
rations according to the method of Cotman (19). Synapto-
somes were suspended in the standard salt solution con-
taining (in mM): NaCl, 126; KCl, 5; CaCl2, 1; MgCl2, 2; NaH2PO4, 
1.0; HEPES-NaOH, 20, pH 7.4; D-glucose, 10, and used in the 
experiments during 2-4 hours after isolation. All buffers and 
synaptosomal suspensions were constantly oxygenated. All 
manipulations were performed at 0-4°C. Protein concen-
tration was measured according to Larson et al (20) with 
bovine serum albumin as a standard.
GaBa uptake experiments
Synaptosomes were diluted with standard salt solution 
containing GABA transaminase inhibitor, aminooxiacetic 
acid 100 μM to minimize the formation of GABA metab-
olites. The concentration of synaptosomal protein in the 
samples was 100 μg/mL. Samples were preincubated for 
15 minutes at 37°C and GABA/[3H]GABA (1 μM/50nM-0.1 
μCi/mL, respectively) were added. GABA uptake was ter-
minated in different time intervals by filtering aliquots 
through Whatman GF/C filters. After washing them twice 
with 5 mL ice-cold standard saline, filters were dried and 
suspended in Organic Counting Scintillant and counted in 
a Delta 300 scintillation counter (Tracor Analytic, Elk Grove 
Village, IL, USA). NO-711 and β-alanine were used as inhibi-
tors of GABA uptake at a concentration of 30 μM and 100 
μM, respectively. Non-specific binding of the neurotrans-
mitter was evaluated in cooling samples sedimented im-
mediately after the addition of radiolabelled GABA. Each 
measurement was performed in triplicate.
statistical analysis
Results are expressed as mean ± standard error of the 
mean of n independent experiments. Difference between 
two groups was compared by two-tailed t-test. Differences 
were considered significant at Р≤0.05.
resuLTs
The effect of the incubation time on the inhibitory 
capacity of NO-711 and β-alanine
In the first sets of the experiments, we assessed how the 
incubation time of synaptosomes with the inhibitors in-
fluenced [3H]GABA uptake. Using cortical synaptosomes, 
it was shown that acute effect of NO-711 (that is, simul-
taneous addition of NO-711 (30 μΜ) and [3H]GABA, which 
starts the uptake process) and the effect after preliminary 
incubation with synaptosomes for 15 minutes were simi-
lar. NO-711 decreased synaptosomal accumulation of [3H]
GABA for 5 minutes by 94.3% in acute treatment and 93.6% 
after 15-minute preincubation (Figure 1A).
The effect of β-alanine, used at a concentration of 100 μΜ, 
was also studied during acute treatment and under condi-
tions of preliminary incubation with synaptosomes. Figure 
1, B shows the time course of [3H]GABA uptake by corti-
cal synaptosomes in the presence of β-alanine. The inhibi-
tor added to synaptosomes simultaneously with [3H]GABA 
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slightly decreased the initial velocity of [3H]GABA uptake 
(by 3.0%) and [3H]GABA accumulation for 5 minutes (by 
6.3%) (Figure 1B, curve 2). However, the preliminary incu-
bation of synaptosomes with β-alanine for 15 minutes de-
creased the initial velocity of uptake and accumulation of 
[3H]GABA for 5 minutes by 14.1% and 21.4%, respectively, 
thereby increasing its inhibitory effect (Figure 1B, curve 3). 
Similar dependence of inhibitory capacity of NO-711 and 
β-alanine on the incubation time was observed in the ex-
periments with hippocampal and thalamic synaptosomes 
(data not shown).
In the next series of the experiments, the effect of NO-711 
and β-alanine on the initial velocity of [3H]GABA uptake by 
cortical, hippocampal, and thalamic synaptosomes isolat-
ed from control rats and rats that underwent hypoxia was 
analyzed. The protocol included preliminary incubation of 
synaptosomes with 30 μΜ NO-711 and 100 μΜ β-alanine 
for 15 minutes.
The effect of NO-711 on [3H]GaBa uptake by cortical, 
hippocampal, and thalamic synaptosomes of control 
rats and rats exposed to perinatal hypoxia
Cortical nerve terminals. In the control group, the initial ve-
locity of [3H]GABA uptake was decreased by 80.1%, from 
150.2 ± 2.4 pmol/min x mg of protein to 29.3 ± 3.9 pmol/
min x mg of protein in the presence of NO-711 (Figure 2, 
the first and second column).
In rats exposed to hypoxia, the initial velocity of [3H]GABA 
was decreased by 9% in comparison with the normal level 
FiGure 1. The effect of NO-711 (30 μM) (A) and β-alanine (100 μM) (B) on [3H]GaBa uptake by cortical synaptosomes. [3H]GaBa 
uptake: 1) control; 2) acute effects of the inhibitors, ie, NO-711 (A) or β-alanine (B) and [3H]GaBa when they are simultaneously added 
to the medium; 3) preliminary incubation of synaptosomes with NO-711 (A) or β-alanine (B) for 15 minutes. Data are presented as 
mean ± standard error of the mean of three independent experiments, each performed with different synaptosomal preparations in 
triplicate.
FiGure 2. The effects of NO-711 at a concentration of 30 μΜ 
(15 minutes preincubation) (the second and fifth column) and 
β-alanine at a concentration of 100 μΜ (15 minutes preincuba-
tion) (the third and sixth column) on the initial velocity of [3H]
GaBa uptake by cortical synaptosomes isolated from control 
rats (the first triplet of column) and rats preliminarily exposed 
to hypoxia and seizures at the age of 10-12 postnatal days (the 
second triplet of columns). Data are presented as mean ± stan-
dard error of the mean of three independent experiments, 
each performed with different synaptosomal preparations in 
triplicate. asterisk – Р≤0.05 as compared to control.
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(Figure 2, the first and fourth column). The initial velocity of 
[3H]GABA uptake was 140.8 ± 1.9 pmol/min x mg of protein 
without NO-711 and 30.7 ± 2.1 pmol/min x mg of protein 
with NO-711 (78.2% decrease). Therefore, the effect of NO-
711 on [3H]GABA uptake was similar in control animals and 
animals exposed to hypoxia (Figure 2, the second and fifth 
column).
Hippocampal nerve terminals. In the control group, the ini-
tial velocity of [3H]GABA uptake was decreased by 84.3%, 
from 178.6 ± 2.8 pmol/min x mg of protein to 28.0 ± 1.1 
pmol/min x mg of protein in the presence of NO-711 (Fig-
ure 3, the first and second column).
In rats exposed to hypoxia, the initial velocity of [3H]GABA 
uptake was by 6% lower than the normal level (Figure 3, 
the first and fourth column) and was 167.7 ± 2.1 pmol/
min x mg of protein. In the presence of NO-711, it was 
32.6 ± 1.2 pmol/min x mg of protein (Figure 3, the fifth 
column). So, NO-711 decreased it by 80.1%. Therefore, the 
effectiveness of NO-711 to influence [3H]GABA uptake 
decreased in animals exposed to hypoxia in comparison 
with the control animals (Figure 3, the second and fifth 
column).
Thalamic nerve terminals In the control group, NO-711 
decreased the initial velocity of [3H]GABA uptake by 79.6%, 
from 142.4 ± 4.8 pmol/min x mg of protein to 29.0 ± 2.1 
pmol/min x mg of protein in (Figure 4, the first and sec-
ond column).
Exposure to hypoxic conditions did not significantly 
change the initial velocity of [3H]GABA uptake by thalamic 
synaptosomes in comparison with the normal level (Fig-
ure 4, the first and fourth column), which was 143.5 ± 4.2 
pmol/min x mg of protein. In the presence of NO-711, it 
was 41.8 ± 3.4 pmol/min x mg of protein (Figure 4, the fifth 
column) (70.9% reduction). Therefore, the effectiveness of 
NO-711 was decreased in animals exposed to hypoxia in 
comparison with the control animals (Figure 4, the second 
and fifth column).
The effect of β-alanine on [3H]GaBa uptake by cortical, 
hippocampal, and thalamic synaptosomes of control 
rats and rats exposed to hypoxia
Cortical nerve terminals. In the control group, the initial ve-
locity of [3H]GABA uptake in the presence of β-alanine was 
decreased by 14.1% and was 129.1 ± 3.8 pmol/min x mg 
of protein (Figure 2, the first and third column).
After exposure to hypoxic conditions, the initial velocity of 
[3H]GABA uptake was 120.0 ± 3.1 pmol/min x mg of pro-
tein (Figure 4, the sixth column) and β-alanine decreased 
it by 15.1%. Therefore, the effectiveness of β-alanine was 
not changed significantly in animals exposed to hypox-
ia compared with control animals (Figure 2, the third and 
sixth column).
Hippocampal nerve terminals. In the control group, the 
initial velocity of [3H]GABA uptake in the presence of 
β-alanine was decreased by 14.4% and was 152.9 ± 4.3 
pmol/min x mg of protein (Figure 3, the first and third 
column).
Under hypoxic conditions, the initial velocity of [3H]GABA 
uptake in the presence of β-alanine was 130.7 ± 3.2 
pmol/min x mg of protein (Figure 3, the sixth column). 
β-alanine decreased the initial velocity of [3H]GABA up-
take by 22.1%. Therefore, the effectiveness of β-alanine 
was increased in animals exposed to hypoxia in compari-
son with the control animals (Figure 3, the third and sixth 
column).
FiGure 3. The effects of NO-711 at a concentration of 30 μΜ 
(15 minutes preincubation) (the second and fifth column) and 
β-alanine at a concentration of 100 μΜ (15 minutes preincuba-
tion) (the third and sixth column) on the initial velocity of [3H]
GaBa uptake by hippocampal synaptosomes isolated from 
control rats (the first triplet of columns) and rats preliminarily 
exposed to hypoxia and seizures at the age of 10-12 postna-
tal days (the second triplet of columns). Data are presented 
as mean ± standard error of the mean of three independent 
experiments, each performed with different synaptosomal 
preparations in triplicate. asterisk – Р≤0.05 as compared to 
control.
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Thalamic nerve terminals. In the control group, the initial 
velocity of [3H]GABA uptake in the presence of β-alanine 
was lower by 20.2% and was equal to 113.6 ± 3.3 pmol/min 
x mg of protein in the presence of β-alanine (Figure 4, the 
first and third column).
After hypoxia, β-alanine decreased the initial velocity of 
[3H]GABA uptake by 30.2% to 100.1 ± 2.5 pmol/min x mg 
of protein (Figure 4, the sixth column). Therefore, the effec-
tiveness of β-alanine was increased in animals exposed to 
hypoxia in comparison with the control animals (Figure 4, 
compare the third and sixth column).
DiscussiON
GABA plays a key role in the regulation of neuronal ex-
citability maintaining the inhibitory tone that counterbal-
ances neuronal excitation. A disturbance in GABAergic 
signaling is involved in the pathogenesis of several CNS 
diseases, including anxiety, sleep disorders, epilepsy, de-
pression, chronic pain, and others. A promising approach 
in the successful treatment of these disorders is the use of 
drugs influencing GABA uptake. Compounds addressing 
GAT1 and GAT3 are of special interest for enhancing GABA 
neurotransmission, and this is especially true for potent 
and selective GAT3 inhibitors as these are lacking so far 
(21). Mixed GAT inhibitors have much broader spectrum 
of anticonvulsant activity than compounds with affinity 
only for GAT1 (8,14). Until now, only tiagabine – a selec-
tive inhibitor of GAT1 transporter has been used in the 
clinic in the treatment of partial seizures. It has been also 
shown to be effective in a variety of non-epileptic condi-
tions, including psychosis, general anxiety and sleep dis-
orders, bruxism, drug addiction, acute and chronic pain, 
tonic spasm, posttraumatic stress, essential tremor, and 
migraine prophylaxis (16).
Hypoxia and seizures early in life can cause multiple neu-
rological deficits and even chronic epilepsy. Imbalance 
between excitation and inhibition is considered to be a 
crucial factor in the etiology of neurological disorders aris-
ing after hypoxia and seizures at an early age. So, it is ex-
tremely important to keep appropriate extracellular con-
centration of excitatory and inhibitory neurotransmitters 
between episodes of regulated exocytosis, ie, fusion of 
synaptic vesicles containing neurotransmitter with the 
plasma membrane (11,22-26). It is still unclear how to 
modulate long-lasting changes in GABA uptake and am-
bient GABA level in different brain regions after perinatal 
hypoxia/seizures if these changes result from altered func-
tioning of different types of GATs.
The initial velocity of high-affinity [3H]GABA uptake and ac-
cumulation of [3H]GABA were assessed in isolated rat brain 
nerve terminals (synaptosomes), which retain all features 
of intact nerve terminals, eg, ability to maintain the mem-
brane potential and exocytotic release, as well as accom-
plish the uptake of the neurotransmitters. Synaptosomes 
promise to be one of the best systems to explore the rela-
tionship between the structure of a protein, its biochemi-
cal and cell-biological properties, and physiological role 
(27). We demonstrated a decrease in the initial velocity of 
[3H]GABA uptake in cortical and hippocampal nerve termi-
nals isolated from rats 8-9 weeks old that preliminary un-
derwent hypoxia and seizures at the age of 10-12 postna-
tal days in comparison with control rats, but we found no 
alterations in the thalamus. These data are in accordance 
with our previous results on the assessment of the extra-
cellular level of [3H]GABA in nerve terminals after perina-
tal hypoxia, where we found a long-lasting increase in 
the ambient [3H]GABA level in cortical and hippocampal 
nerve terminals, whereas the thalamus was less sensi-
tive (11). Taking into account that the main types of 
FiGure 4. The effects of NO-711 at a concentration of 30 μΜ 
(15 minutes preincubation) (the second and fifth column) and 
β-alanine at a concentration of 100 μΜ (15 minutes preincuba-
tion) (the third and sixth column) on the initial velocity of [3H]
GaBa uptake by thalamic synaptosomes isolated from control 
rats (the first triplet of columns) and rats preliminary exposed 
to hypoxia and seizures at the age of 10-12 postnatal days (the 
second triplet of columns). Data are presented as mean ± stan-
dard error of the mean of three independent experiments, 
each performed with different synaptosomal preparations in 
triplicate. asterisk – Р≤0.05 as compared to control.
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GABA transporters, which determine the optimal ambient 
level of GABA in the brain, are GAT1 and GAT3, we analyzed 
the effects of highly selective blocker of GAT1, NO-711, and 
substrate inhibitor of GAT3, β-alanine, on [3H]GABA uptake 
by nerve terminals. It was shown that the inhibitory capac-
ity of NO-711 and β-alanine was not changed after perina-
tal hypoxia in cortical synaptosomes. The inhibitory capac-
ity of β-alanine to influence GABA uptake was increased 
in hippocampal and thalamic nerve terminals as a result 
of perinatal hypoxia, whereas the capacity of NO-711 in 
thalamic nerve terminals was decreased. Taking into ac-
count our data on the effect of NO-711 and β-alanine in 
the thalamus, it may be speculated that surface expression 
of GAT1 and GAT3 was changed after perinatal hypoxia, 
thereby representing the compensatory mechanism un-
derlying the maintenance of the optimal ambient level of 
GABA. In contrast, there were no alterations in the inhibito-
ry capacity of NO-711 and β-alanine in the cortex that may 
reflect the unchanged ratio GAT1/GAT3 after perinatal hy-
poxia. Recently, we have shown that perinatal hypoxia did 
not change the affinity of GATs to substrate in the cortex, 
hippocampus, and thalamus (11), so it may be suggested 
that alteration in the effectiveness of the inhibitors after 
perinatal hypoxia is more associated with the changes in 
the number of the transporters in the plasma membrane 
than with the affinity of the inhibitors to substrate-binding 
site of GATs.
It is not new that hypoxia changes the expression of dif-
ferent types of GATs. Melone et al (28) showed that tran-
sient focal ischemia triggered a novel neuronal expression 
of GAT3 in the rat perilesional cortex. Dalby et al (8) sug-
gested that the ratio of GAT1/GAT3 affinity was very im-
portant for the efficacy of non-selective GABA uptake in-
hibitors in epilepsy. GAT3-mediated GABA uptake comes 
into play only under specific physiological or pathological 
conditions, which results in an increase in neuronal activ-
ity and GABA release beyond normal levels in the striatum 
(29). It was demonstrated that protein kinase C activation 
induced serine/threonine phosphorilation of GAT1, which 
in turn promoted GAT1 internalization, and also in the pres-
ence of tyrosine kinase activators the insertion of GAT1 to 
the plasma membranes was accelerated (30).
Experiments with exogenously applied β-alanine are es-
pecially interesting because this molecule can be readily 
absorbed from the gastrointestinal tract and transported 
into the CNS. β-alanine is carried across the BBB into the 
CNS via a taurine-sensitive β-amino acid transporter in 
a Na+ and Cl--dependent manner. This transporter is 
highly selective for β-amino acids because neither L-glu-
tamate (transported by the anionic amino acid transport-
er) nor L-phenylalanine (transported by the large neutral 
amino acid transporter) affects the movement of β-alanine 
across the BBB. β-alanine may also cross the BBB by passive 
diffusion (17). Analogues of β-alanine are proposed for a 
treatment of epilepsy and as a basis for antiepileptic drug 
design (31). When orally administered, plasma concentra-
tions of β-alanine rise rapidly, peaking within 30-45 min-
utes, then dropping significantly within 90-120 minutes 
(32). Despite being a simple amino acid, β-alanine remains 
essentially unexplored as either a neurological drug or a 
drug design platform (33).
Our data on the effects of β-alanine can be interesting 
also because β-alanine exhibits physiological significance. 
β-alanine is widely distributed throughout the brain, and 
is one of only a few naturally occurring β-amino acids en-
dogenous to humans and mammals. The average con-
centrations of β-alanine within the brain are between 0.03 
and 0.08 mM. A detailed examination of β-alanine con-
centrations in rat brain has shown that β-alanine shows 
regional differences: midbrain contains the highest con-
centration (0.108 mmol/g frozen weight); the cortex con-
tains just over half of this value (0.065 mmol/g), while 
the cerebellum contains the lowest concentration (0.039 
mmol/g). Regional distribution of β-alanine in the CNS is 
an important attribute of a neurotransmitter substance 
(17). This variation of β-alanine concentrations in the CNS 
is similar to variable concentrations for GABA (12). In the 
CNS, β-alanine acts as a depressant of neuronal activity 
with the potency comparable to that of the neurotrans-
mitter GABA. Nevertheless, the role of β-alanine in sleep, 
consciousness, epilepsy, stroke, and other disorders re-
quires greater clarification (17). In this context, our data 
may be also of value for the analysis of possible inter-syn-
aptic crosstalk between GABA- and β-alanine-ergic nerve 
terminals. In this case, released β-alanine can cause inhi-
bition of non-GAT1-mediated uptake of GABA. Moreover, 
Mathers et al (34) has recently shown that chemical trans-
mission at the inhibitory synapses in the thalamus in-
volves receptor activation by β-alanine. The importance 
of β-alanine for synaptic transmission is supported by 
the fact that the patients with β-alaninemia (accumula-
tion of β-alanine as inborn error of metabolism) may de-
velop neurological abnormalities whose mechanisms are 
far from being understood (35).
It has to be underlined that except GABA transporters, 
β-alanine has five recognized receptor sites: glycine coag-
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onist site on the NMDA (N-methyl-D-aspartate) complex; 
glycine receptor site; GABA-A receptor, and GABA-C re-
ceptor (33). As imbalance between excitation and inhibi-
tion is considered a crucial factor in the etiology of neuro-
logical disorders arising after hypoxia and seizures at early 
age, there may be a wide range of β-alanine applications 
including complementary regulation of GABA- and gluta-
mate-ergic neurotransmission.
Therefore, we showed that the efficacy of β-alanine to 
inhibit GABA uptake was increased in hippocampal and 
thalamic nerve terminals as a result of perinatal hypoxia, 
whereas the capacity of NO-711 in thalamic nerve termi-
nals was decreased. This might result from the alterations 
in the ratio of active GAT1/GAT3 expressed in the plasma 
membrane of nerve terminals after perinatal hypoxia. This 
fact shows a possibility of targeted modulation of GAT3 
transporter activity and GABAergic neurotransmission un-
der pathological conditions by exogenous and endoge-
nous naturally occurring β-alanine.
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